Detalles de la búsqueda
1.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38634928
2.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676282
3.
Antibody-drug conjugates for lung cancer in the era of personalized oncology.
Semin Cancer Biol
; 69: 268-278, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31899248
4.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Oncologist
; 27(2): 87-e115, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641222
5.
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study.
Oncologist
; 27(9): e723-e730, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35815922
6.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462870
7.
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
BMC Cancer
; 22(1): 915, 2022 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35999527
8.
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Oncologist
; 26(10): e1854-e1861, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34101934
9.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34167578
10.
Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Radiol Med
; 126(8): 1117-1128, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33954898
11.
Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
Int J Mol Sci
; 22(9)2021 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33922388
12.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1177-1187, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140762
13.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1189, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32347358
14.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
15.
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings.
Radiol Med
; 125(2): 214-219, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605353
16.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31669155
17.
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
Br J Cancer
; 120(1): 57-62, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30377342
18.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist
; 24(6): e327-e337, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30796151
19.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413378
20.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet
; 389(10072): 917-929, 2017 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28126333